July 27, 2015 FDA: Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment Over the Spectrum of Disease
April 23, 2015 The TREAT-NMD Advisory Committee for Therapeutics (TACT): An Innovative de-Risking Model to Foster Orphan Drug Development
